Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Visa Inc. (V): Among Morgan Stanley’s Best Stock Picks for 2025

We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to take a look at where Visa Inc. (NYSE:V) stands against Morgan Stanley’s other stock picks.

The tail end of 2024 is seeing a market shift in the stock market as the Federal Reserve has finally signaled that interest rate cuts are on the horizon. This means that cheaper capital might be on the horizon, with the rate cuts coming just as the labor market starts to feel the pinch through lower growth.

It also means that consumer spending can pick up if economic output remains robust. For investors, it creates an opportunity to gain an early foothold into stocks that could benefit from the new environment. On this front, investment banks have been analyzing the situation diligently for quite some time.

One bank that’s out with regular reports is Morgan Stanley. It releases monthly reports that cover the latest trends in the economy and the stock market. The bank’s August report covered some recent trends. It shared that the labor market was one of its most closely watched economic indicators as it was “vulnerable to a further deceleration in economic activity.” To explain why, the bank shared that US excess labor supply, that is the demand minus supply, was at pre pandemic levels that had sustained since 2018. This implies that employers no longer have the incentive to offer lucrative pay packages to attract workers, which in turn leads to less money flowing into the economy to contribute to inflation.

MS added that the three month national unemployment average was 0.5% above the 12 month average, which is a warning bell for the economy. This is because according to one of the most widely used recession indicators, the Sahm Rule, a recession has started once the rate is 0.5% or higher than the 12 month average. MS is not the only one that is ringing warning bells on this front, as JPM also confirmed in early August that the rule was triggered when the unemployment rate jumped to 4.3%. However, it did add that we “do not think a recession is imminent” and “remain constructive on U.S. equities despite increased volatility, and see opportunity to lock in rates before they fall.”

SEE ALSO 15 Best European AI Stocks According to Morgan Stanley and Best Humanoid Robot Stocks According to Morgan Stanley

Returning to MS, it also sees an opportunity in the battered commercial real estate market. It cites the commercial real estate cap rate, which is the rate of return based on its income generation capability, to argue that commercial real estate valuations are currently depressed enough to warrant an investment. The office real estate market had a cap rate of 9% in March 2024 as per MS, for a two percentage point and three percentage point lead over retail and residential real estate, respectively. As for the stock market, the bank shared in August that it still prefers large cap stocks (an important point as you’ll find out when you check out the stocks in this piece).

The bank believes that small caps “are lower in quality, more volatile and carry greater exposure to cyclical sectors relative to large cap,” meaning that their outperformance “requires economic growth acceleration with lower interest rates.” MS warned that “softer economic data may constrain” small cap performance. In terms of data, it argues that small cap performance is dependent on bond yields. This data set shows that when we assume an index value of 100 for US small caps had led benchmark S&P stocks except the Magnificent 7 at a time when 10 year US bond yields were around 1.5% in July 2021, the indexed returns dropped to 90 in July 2023 when the yields were approximately 4.3%.

August’s final week was pivotal for the stock market as Fed Chair Jerome Powell finally signaled that the time for interest rates had come. “The time has come for policy to adjust,” stated Powell at Jackson Hole, Wyoming. “The direction of travel is clear, and the timing and pace of rate cuts will depend on incoming data, the evolving outlook, and the balance of risks,” he added.

Following the Fed Chair’s remarks, MS was out with its September report. Commenting on the economy, the bank shared that it does not “believe the economy is set to accelerate over the next few months, which makes the S&P 500 around 5650 our near-term upper bound. At the same time, the economy is not collapsing, which makes 5200 attractive and 5350 seem fair. We plan to trade around the ranges.” MS also shares key details for the unemployment rate, which are important when analyzed in tandem with the Sahm Rule. It comments that higher immigration “may be supporting a higher labor force participation rate, which in turn would contribute to a higher reported unemployment rate. From this perspective, a higher unemployment rate is not signaling weakness but rather an increase in the labor supply that would help bring inflation down without affecting growth.”

Subsequently, the bank believes that the percentage of total unemployed accounted for by people who lost their jobs (Job Losers) and the number of total layoffs (Challenger Layoffs) might be more relevant when analyzing the labor market. Job Losers currently sit at 50%, while Challenger Layoffs are less than 50,000 after having jumped to 100,000. In short, this paints a more robust labor market picture that might not signal a recession as the Sahm Rule might have suggested.

Remaining bearish on small caps, it believes that the “window for small cap outperformance is too narrow – requiring “Goldilocks” growth and inflation.” This sentiment is also echoed in the bank’s Vintage Values 2025 stock report, where it comments that its strategists “currently recommend avoiding small caps, and Vintage Values 2025 reflects that view. It skews heavily toward large-cap stocks: 80% of the names are classified as either mega-cap or large-cap.” Mind you, this sentiment was also echoed in the 2024 report, verbatim.

Our Methodology

To make our list of MS’ top stocks for 2025, we ranked MS’ Vintage Value 2025 stock picks by their share price percentage upside based on the bank’s price target.

For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

A close-up of a modern payments terminal with a pile of credit cards on the side.

Visa Inc. (NYSE:V)

Number of Hedge Fund Holders In Q2 2024: 163

Share Price Target Upside: 12%

Share Price Target: $322

Visa Inc. (NYSE:V) is one the world’s largest payment processors, which lends it a considerable market share and a sizeable moat. It accounts for 61% of the US market by purchase volume, implying that as opposed to growth, customer retention and cost and control are central tenets of the firm’s hypothesis. The former bit is particularly important owing to the rise of digital wallets and the propensity of businesses to avoid dealing with firms like Visa Inc. (NYSE:V) due to high transaction fees. On this front, the firm made history in 2024, when it and smaller rival Mastercard agreed to a whopping $30 billion settlement to help resolve these problems. However, the deal is currently on hold as of June, and if it fails to clear the courts, then Visa Inc. (NYSE:V) could see headwinds to the stock price. The firm, along with Mastercard, also offers 30 day fraud liability protection to consumers, which could become another thorny point with retailers. However, Visa Inc. (NYSE:V) is also improving its service and targeting growth by announcing features such as A2A that allow easy recurring bill payments and expansion into the developing world to target untapped populations.

Aoris Management mentioned Visa Inc. (NYSE:V) in its Q2 2024 investor letter. Here is what the firm said:

“Visa operates the world’s largest payments network, which facilitates the movement of money between merchants, financial institutions, consumers, businesses, and governments.

The company is best known for enabling consumers to make debit and credit card payments. In the year to September 2023, 4.3 billion Visa cardholders made 213 billion transactions on its network, to a total value of US$12.1 trillion.

Compared to cash and cheques, which are still widely used around the world, Visa’s network is a more convenient, secure, and ubiquitous way for consumers to pay. Visa has invested to reduce friction and fraud in the payments experience, to the benefit of both merchants and consumers.”

Overall V ranks 11th on our list of Morgan Stanley’s best stock picks for 2025. While we acknowledge the potential of V as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than V but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…